HC Wainwright & Co. Maintains Buy on BioCryst Pharma, Maintains $32 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 92.4%

Neg 0% Neu 92.4% Pos 0%

HC Wainwright & Co. analyst Andrew S. Fein maintains BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $32 price target.